Indacaterol: a novel long-acting β(2) -agonist

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Bronchodilators, specifically beta-2 agonists and anticholinergics, are primary treatments for chronic obstructive pulmonary disease (COPD).
• Existing beta-2 agonists include short-acting (multiple daily doses) and long-acting (twice-daily administration) formulations.
• Indacaterol represents an advancement as an ultra-long-acting beta-2 agonist approved in the US, enabling once-daily dosing.

Purpose of the Study:

• To evaluate the efficacy and safety of indacaterol, a novel ultra-long-acting beta-2 agonist, for COPD management.
• To compare the benefits of once-daily indacaterol administration with existing bronchodilator therapies.

Main Methods:

• Clinical evaluation of indacaterol's pharmacokinetic profile, focusing on its 24-hour duration of action.
• Assessment of adverse effects, particularly cough, associated with indacaterol inhalation.
• Comparison of spirometric measurements between indacaterol and other bronchodilator treatments.

Main Results:

• Indacaterol provides approximately 24 hours of bronchodilation, facilitating once-daily dosing.
• Cough was the most frequent adverse event, occurring shortly after inhalation, brief in duration, and not linked to bronchospasm or treatment cessation.
• Indacaterol demonstrated a safety profile similar to other bronchodilators.

Conclusions:

• Indacaterol's once-daily dosing offers convenience for patients with mild-to-moderate COPD.
• Its comparable efficacy to other bronchodilators suggests potential benefit as monotherapy or in combination with once-daily anticholinergics.